Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report 2026

The ribose-nucleic acid (rna)-based therapeutics market size has grown strongly in recent years. It will grow from $17.22 billion in 2025 to $18.75 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to advancements in molecular biology research, initial success of rna-based drugs, expansion of genetic disease research, increased pharmaceutical r&d investments, growing understanding of gene regulation.

The ribose-nucleic acid (rna)-based therapeutics market size is expected to see strong growth in the next few years. It will grow to $26.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing regulatory approvals for rna therapies, rising demand for personalized medicine, expansion of oncology-focused rna pipelines, growing investments in delivery technologies, increasing collaborations between biotech firms. Major trends in the forecast period include increasing development of rna-based targeted therapies, rising use of sirna and aso technologies, growing focus on rare and genetic disorders, expansion of clinical trials for rna therapeutics, enhanced drug delivery system innovations.

The rising prevalence of cancer is anticipated to drive the growth of the ribose-nucleic acid (RNA)-based therapeutics market in the coming years. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells, which can be fatal if not treated effectively. The increasing incidence of cancer is attributed to factors such as an aging global population, lifestyle changes, greater exposure to environmental and behavioral risk factors, and improvements in screening and diagnostic techniques. RNA-based therapeutics represent a promising approach to cancer treatment by directly targeting the genetic and molecular pathways involved in tumor development and progression. For example, in August 2023, according to the Australian Institute of Health and Welfare, an Australia-based government health agency, approximately 151,000 individuals were diagnosed with cancer in 2021, excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin, and this number is projected to increase to about 185,000 by 2030. Therefore, the increasing prevalence of cancer is driving the growth of the ribose-nucleic acid (RNA)-based therapeutics market.

Major companies operating in the ribose-nucleic acid (RNA)-based therapeutics market are concentrating on the development of innovative drug solutions, such as messenger RNA (mRNA)-based booster vaccines, to improve immunization effectiveness, address emerging viral variants, and enhance the durability of immune responses. An mRNA-based booster vaccine works by delivering messenger RNA that instructs cells to produce a specific protein, thereby stimulating and strengthening the body’s immune response against a targeted pathogen. For instance, in June 2023, Gennova Biopharmaceuticals Ltd., an India-based pharmaceutical company, launched GEMCOVAC-OM, India’s first mRNA booster vaccine designed specifically to target the Omicron variant of COVID-19. This booster was developed to address the reduced effectiveness of earlier vaccines against the Omicron strain. By leveraging mRNA technology, GEMCOVAC-OM enhances immune protection and provides improved defense against evolving viral variants.

In May 2024, Orna Therapeutics, a US-based biotechnology company focused on RNA-based therapeutic development, acquired ReNAgade Therapeutics for an undisclosed amount. Through this acquisition, Orna aims to strengthen its technological capabilities by combining its circular RNA expression platform with ReNAgade’s lipid nanoparticle (LNP)-based RNA delivery technologies and RNA editing programs. ReNAgade Therapeutics is a US-based biotechnology company specializing in the development of RNA-based therapeutics.

Major companies operating in the ribose-nucleic acid (rna)-based therapeutics market are F Hoffmann La Roche AG, Eli Lilly And Company, Novo Nordisk AS, Regeneron Pharmaceuticals, Biogen Inc., BioNTech, Alnylam Pharmaceuticals, Sarepta Therapeutics, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics, Moderna Inc., CureVac NV, Silence Therapeutics plc, ProQR Therapeutics NV.

North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2025. The regions covered in the ribose-nucleic acid (rna)-based therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ribose-nucleic acid (rna)-based therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the RNA-based therapeutics market by increasing costs of imported nucleotides, delivery vectors, manufacturing equipment, and laboratory reagents used in drug development and production. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces cost pressure on clinical trial supplies. These tariffs increase development costs and extend commercialization timelines. However, they also encourage domestic manufacturing, local sourcing of raw materials, and strengthened regional biopharmaceutical supply chains.

The ribose-nucleic acid (rna)-based therapeutics market research report is one of a series of new reports that provides ribose-nucleic acid (rna)-based therapeutics market statistics, including ribose-nucleic acid (rna)-based therapeutics industry global market size, regional shares, competitors with a ribose-nucleic acid (rna)-based therapeutics market share, detailed ribose-nucleic acid (rna)-based therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the ribose-nucleic acid (rna)-based therapeutics industry. This ribose-nucleic acid (rna)-based therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ribose-nucleic acid (RNA)-based therapeutics refer to a category of medical treatments that use RNA molecules to regulate cellular processes, usually by targeting specific genetic sequences. These therapies are developed to treat a wide range of conditions, including genetic disorders, cancers, and infectious diseases, by altering gene expression, protein synthesis, or cellular signaling pathways.

The main types of ribose-nucleic acid (RNA)-based therapeutics include RNA interference (RNAi) and RNA antisense therapies. RNA interference (RNAi) is a biological mechanism in which RNA molecules suppress gene expression or translation by neutralizing specific messenger RNA (mRNA) targets. The associated technologies include enabling technologies. These therapies are applied across various therapeutic areas such as oncology, genetic disorders, ophthalmology, hematological disorders, acute hepatic porphyria (AHP), and others, and are used by end users including research institutes, hospitals, and clinics.

The ribose-nucleic acid (RNA)-based therapeutics market consists of revenues earned by entities by custom synthesis of RNA, RNA delivery systems, and RNA sequencing analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribose-nucleic acid (RNA)-based therapeutics market also includes the sale of microRNA (miRNA) therapeutics, antisense oligonucleotides, and messenger RNA (mRNA) vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.